Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial

In an open‐label, 24‐month trial, 721 de novo heart transplant recipients were randomized to everolimus 1.5 mg or 3.0 mg with reduced‐dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard‐dose cyclosporine (plus corticosteroids ± induction). Primary efficacy endpoint was the 12‐mon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2013-05, Vol.13 (5), p.1203-1216
Hauptverfasser:	Eisen, H. J., Kobashigawa, J., Starling, R. C., Pauly, D. F., Kfoury, A., Ross, H., Wang, S.‐S., Cantin, B., Van Bakel, A., Ewald, G., Hirt, S., Lehmkuhl, H., Keogh, A., Rinaldi, M., Potena, L., Zuckermann, A., Dong, G., Cornu‐Artis, C., Lopez, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Anti-Inflammatory Agents, Non-Steroidal Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antineoplastic Agents Antiviral agents Asia - epidemiology Australia - epidemiology Biological and medical sciences Biopsy Cardiac allograft vasculopathy cyclosporine Dose-Response Relationship, Drug Europe - epidemiology Everolimus Female Follow-Up Studies Graft Rejection - diagnosis Graft Rejection - drug therapy Graft Rejection - epidemiology Heart Transplantation Humans Immunosuppressive Agents - administration & dosage Incidence Male Medical sciences Middle Aged mycophenolate mofetil Mycophenolic Acid - administration & dosage Mycophenolic Acid - analogs & derivatives Myocardium - pathology North America - epidemiology Pharmacology. Drug treatments Prospective Studies randomized Sirolimus - administration & dosage Sirolimus - analogs & derivatives South America - epidemiology Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the heart Treatment Outcome Ultrasonography, Interventional
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!